Clover Health Investments Corp (CLOV) Clearly Signals Buy-Into the Stock: Don’t ignore the signals

With 3.22 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.46 shares. During the session, the Healthcare Plans company that operates in wider Healthcare sector, reached to the highest price of $1.0400 whereas the lowest price it dropped to was $0.9893. The 52-week range on CLOV shows that it touched its highest point at $1.63 and its lowest point at $0.71 during that stretch. It currently has a 1-year price target of $1.33. Beta for the stock currently stands at 1.92.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CLOV was up-trending over the past week, with a rise of 2.50%, but this was up by 5.84% over a month. Three-month performance surged to 13.09% while six-month performance fell -22.73%. The stock lost -18.40% in the past year, while it has gained 7.13% so far this year. A look at the trailing 12-month EPS for CLOV yields -0.47 with Next year EPS estimates of -0.18. For the next quarter, that number is -0.14. This implies an EPS growth rate of 41.55% for this year and 56.67% for next year.

Float and Shares Shorts:

At present, 381.93 million CLOV shares are outstanding with a float of 369.84 million shares on hand for trading. On Jan 31, 2024, short shares totaled 27.68 million, which was 5.68% higher than short shares on Dec 29, 2023. In addition to Mr. Vivek Garipalli as the firm’s Co-Founder & Executive Chairman, Mr. Andrew Toy serves as its Co-Founder, CEO & Director.

Institutional Ownership:

Through their ownership of 24.81% of CLOV’s outstanding shares, institutional investors have minority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CLOV since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CLOV analysts setting a high price target of $2.00 and a low target of $1.00, the average target price over the next 12 months is $1.33. Based on these targets, CLOV could surge 96.08% to reach the target high and fall by -1.96% to reach the target low. Reaching the average price target will result in a growth of 30.39% from current levels.

Summary of Insider Activity:

Insiders traded CLOV stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 5,079 shares were sold. The number of buy transactions has increased to 13 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 5,238,787 while 1,913,771 shares were sold.